Registered title, quoted from ClinicalTrials.gov
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Renji Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05926726, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically-confirmed hepatocellular carcinoma (HCC)
Inclusion criterion 5
Barcelona Clinic Liver Cancer (BCLC) stage C or B and Child-Pugh ≤7
Inclusion criterion 11
Another primary malignancy within 3 years (with some exceptions for completely-resected early-stage tumors)
Exclusion criterion 4
Non-hematological AEs induced by previous treatment must have recovered to CTCAE ≤1, except for alopecia and peripheral neuropathy
Inclusion criterion 15
Eastern Cooperative Oncology Group (ECOG) performance status scale ≤1
Inclusion criterion 4
Per RECIST v1.1, at least one measurable lesion
Inclusion criterion 9
Active HCV, HIV, or syphilis
Exclusion criterion 7
Women of childbearing potential must agree to use an effective and reliable contraceptive method during 28 days prior to lymphodepletion to 1 year post infusion; Male patients who have not undergone vasectomy and have sexual activity with women of childbearing potential must agree to the use of a barrier contraceptive method since lymphodepletion to 1year post infusion, and sperm donation is prohibited during the study
Inclusion criterion 16
Pregnant or lactating women
Exclusion criterion 15
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05926726, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 18-75 years-old, male or female
- Voluntarily willing to participate in the study and sign the written informed consent form
- Life expectation ≥12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status scale ≤1
- Histologically-confirmed hepatocellular carcinoma (HCC)
- No benefits from curative surgery or other local therapies are expected at screening, judged by investigators
- Radiologically-confirmed progression disease after at least one prior line of systematic treatment and limited benefits from current guideline or consensus for hepatocellular carcinoma are expected at screening, judged by investigators
- Fresh samples or FFPE, immunohistochemistry (IHC)-stained GPC-3 positive with intensity ++ or +++
- Per RECIST v1.1, at least one measurable lesion
- Manageable lung metastasis
- Barcelona Clinic Liver Cancer (BCLC) stage C or B and Child-Pugh ≤7
- No active HBV infections
- Adequate organ functions
- Adequate venous access for APH
- Non-hematological AEs induced by previous treatment must have recovered to CTCAE ≤1, except for alopecia and peripheral neuropathy
- Women of childbearing potential must agree to use an effective and reliable contraceptive method during 28 days prior to lymphodepletion to 1 year post infusion; Male patients who have not undergone vasectomy and have sexual activity with women of childbearing potential must agree to the use of a barrier contraceptive method since lymphodepletion to 1year post infusion, and sperm donation is prohibited during the study
- Women of childbearing potential must have negative serum β-hCG test result at screening and 48 hours prior to lymphodepletion
Exclusion Criteria:
- Cholangiocarcinoma or histological-mixed hepatocellular cholangiocarcinoma
- Active brain metastasis
- Primary lesion or infused lesions with the longest diameter ≥15cm, or other potential risk which might not be appropriate for further study treatment judged by the investigator
- Another primary malignancy within 3 years (with some exceptions for completely-resected early-stage tumors)
- Systematic autoimmune disorders requiring long-term systematic immunosuppression
- Previously treated with any genetically engineered modified T cell therapy (TCR-T/CAR-T) or other CGT
- Active HCV, HIV, or syphilis
- History of organ transplant
- Uncontrolled or active infection at screening, prior to APH, 72 hours prior to lymphodepletion or 5 days prior to JWATM214 infusion
- With severe cardiovascular disease
- History or presence of clinically-relevant CNS disorders
- Current presence of hepatic encephalopathy
- ≥G2 hemorrhage within 30 days prior to screening, or in need of long-term anticoagulants
- Active digestive ulcer or gastrointestinal bleeding within 3 months prior to screening
- Pregnant or lactating women
- Not satisfying wash-out period for APH
- Unable or unwilling to comply with the study protocol, judged by the investigator
- Other situations implying that the subject might not be appropriate to participate in the study
- Previously allergic or intolerable to JWATM214 or its components
Quoted from ClinicalTrials.gov, NCT05926726, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05926726, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.